Coronary Artery Disease and Myocardial Infarction

AHA 23: Preventive Cardiology in 2023

Michael Honigberg,

Watch time: 7m 3s
AHA 23: The ORFAN Study

Charalambos Antoniades,

Watch time: 10m
TCT 23: IFR SWEDEHEART

Matthias Gotberg,

Watch time: 7m 14s

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 1h 35m 42s (16 videos)
ESC 23: LIBerate-HeFH Study

Frederick Raal,

Watch time: 4m 16s
ESC 23 Late-Breaker Discussion: The RECORD MI Registry

Harriette Van Spall, Javed Butler,

Watch time: 9m 37s
ESC 23: The ILUMIEN IV Trial

Ziad A Ali,

Watch time: 4m 12s
ESC 23: OCEAN(a)-DOSE Trial Update

Michelle O'Donoghue,

Watch time: 3m 22s
ESC 23: LODESTAR Trial

Myeong-Ki Hong,

Watch time: 3m 42s

Yugo Yamashita,

Joost Daemen, Allen Jeremias, Ziad A Ali, et al

Watch time: 55m 46s (1 video)
ACC 23: Lipid Management & the CLEAR Trial with Dr Michos

Erin D Michos,

Watch time: 5m 34s

Heather Currie , Christine Williams ,

Read time: 10m

Edward T Carreras , Donna M Polk ,

FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s

Sergio Fazio ,

Charles H Hennekens , Danielle Hollar , Arthur S Agatston ,

Marc Sirol ,

Abdulah Alrifai , Mohamad Kabach , Jonathan Nieves , et al

Marsha M Neumyer , Bill Bertolino ,

Read time: 11m

Donald E Cutlip ,

Yassir Javaid, , , et al

Watch time: 1h 7m 2s (4 videos)

Antonio Gutierrez , Sunil V Rao ,

Media

AHA 23: Preventive Cardiology in 2023

Michael Honigberg,

Watch time: 7m 3s

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 1h 35m 42s (16 videos)
ESC 23 Late-Breaker Discussion: The RECORD MI Registry

Harriette Van Spall, Javed Butler,

Watch time: 9m 37s
ESC 23: The ILUMIEN IV Trial

Ziad A Ali,

Watch time: 4m 12s

Yugo Yamashita,

Joost Daemen, Allen Jeremias, Ziad A Ali, et al

Watch time: 55m 46s (1 video)
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study

Annapoorna Kini ,

Watch time: 8m 1s
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen,

Watch time: 16m 12s
View from the Thoraxcenter: What's Hot at ACC.23?

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 22m 4s
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue,

Watch time: 14m 28s
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 20s
FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s

Media

AHA 23: The ORFAN Study

Charalambos Antoniades,

Watch time: 10m
TCT 23: IFR SWEDEHEART

Matthias Gotberg,

Watch time: 7m 14s

Joost Daemen, Allen Jeremias, Ziad A Ali, et al

Watch time: 55m 46s (1 video)

Yugo Yamashita,

ESC 23: The ILUMIEN IV Trial

Ziad A Ali,

Watch time: 4m 12s
ESC 23 Late-Breaker Discussion: The RECORD MI Registry

Harriette Van Spall, Javed Butler,

Watch time: 9m 37s
AHA 23: Preventive Cardiology in 2023

Michael Honigberg,

Watch time: 7m 3s

Yassir Javaid, , , et al

Watch time: 1h 7m 2s (4 videos)
ESC 23: OCEAN(a)-DOSE Trial Update

Michelle O'Donoghue,

Watch time: 3m 22s
ESC 23: LODESTAR Trial

Myeong-Ki Hong,

Watch time: 3m 42s
ESC 23: LIBerate-HeFH Study

Frederick Raal,

Watch time: 4m 16s

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 1h 35m 42s (16 videos)

Articles

Guest Editorial: A Brave New World for Non-vitamin K Antagonist Oral Anticoagulants: Have We seen the Last of Warfarin?

Michela Faggioni

,

Michael C Gibson

,

Roxana Mehran

,

Citation:

US Cardiology Review 2017; 11(1):37–8

DOI:

https://doi.org/10.15420/usc.2017:6:1.GE
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 543
  • Downloads: Downloads 3

Dual Anti-platelet Therapy after Coronary Stenting: Rationale for Personalized Duration of Therapy

Donald E Cutlip

,

Citation:

US Cardiology Review 2017;11(1):31–6

DOI:

https://doi.org/10.15420/usc.2017:7:2
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 4397
  • Downloads: Downloads 9
  • Citations: 1

What the Cardiologist Needs to Know About Medications for Type 2 Diabetes

Stephen Ku

,

Steven V Edelman

,

Citation:

US Cardiology Review 2016;10(2):54–9

DOI:

https://doi.org/10.15420/usc.2016:4:2
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 1567
  • Downloads: Downloads 7

Pharmacologic Strategies for Management of Pulmonary Arterial Hypertension

Rebecca L Attridge

,

Rebecca D Moote

,

Deborah J Levine

,

Citation:

US Cardiology Review 2016;10(2):78–84

DOI:

https://doi.org/10.15420/usc.2016:2:2
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 2473
  • Downloads: Downloads 18